Level C· Early human research exploring benefitsCohort StudyPubMedOpen access

Preclinical and early clinical safety of intra-articular spheroid adipose-derived stem cells for knee osteoarthritis: A translational study.

Sobajima S., Harada Y., Kim TS., Kisaki O., Otera K., Yamauchi H.

Cohort Study with a reported sample of 3 on Knee Osteoarthritis, Osteoarthritis, published in Osteoarthr Cartil Open (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Osteoarthr Cartil Open (2026)
Country
England
Reported sample size
3
Source database
PubMed
PMID
42006954
PMCID
PMC13090708
DOI
10.1016/j.ocarto.2026.100792

Abstract (original English)

Objective To evaluate preclinical and early clinical safety of intra-articular spheroid adipose-derived stem cells (S-ADSCs) for knee osteoarthritis and to summarize exploratory outcomes. Methods This program included a minipig study ( n = 3; Day 31) and a clinical cohort ( n = 5; Week 52). Each knee received 42,000 spheroids (500 cells/spheroid; 2.1 × 10 7 cells) in 5 mL. Preclinical assessments included clinical monitoring, laboratory tests, necropsy, and H&E histology of distal femur, proximal tibia, and medial/lateral menisci. In patients, adverse events and serious adverse events were captured through Week 52; exploratory outcomes included pain (visual analog scale [VAS]) and function (KOOS and WOMAC). Exploratory quadratic mixed-effects models assessed non-linear time trends. Results Minipigs showed no abnormal clinical signs, laboratory changes, or treatment-related findings at necropsy or on knee histology through Day 31. All five patients completed 52-week follow-up; no treatment-related adverse events or serious adverse events, infections, hemarthroses, or acute post-injection flares requiring medical treatment occurred. Exploratory outcomes were heterogeneous: two participants showed sustained improvement through Week 52, whereas the remaining three showed non-sustained patterns; two improved early with partial return toward baseline, and one experienced transient pa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research